Effect of lovastatin on intimal hyperplasia after balloon angioplasty: a study in an atherosclerotic hypercholesterolemic rabbit

Department of Medicine, Yale University, School of Medicine, New Haven, Connecticut 06510.

Restenosis, the major limitation of balloon angioplasty, is the result of intimal hyperplasia after the procedure. Lovastatin, a 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) inhibitor, may influence intimal hyperplasia by lowering serum cholesterol and by blocking deoxyribonucleic acid (DNA) synthesis. To determine whether lovastatin reduces intimal hyperplasia, a prospective, randomized blinded study was performed in 60 atherosclerotic New Zealand White male rabbits. Atherosclerosis was produced by air desiccation injury followed by a 28 day diet of 2% cholesterol and 6% peanut oil that was terminated before balloon angioplasty was performed. Angioplasty could not be performed in 14 rabbits with bilateral femoral artery occlusion, and in one rabbit the procedure was a technical failure. Forty-five rabbits underwent balloon angioplasty performed with use of a 2.5-mm balloon inflated to 10 atm for three 1 min dilations at 1 min intervals. Seven rabbits died during the procedure. Thirty-eight rabbits were randomized to either a lovastatin group (6 mg/kg body weight per day) or a control group. Angioplasty was performed on all patent vessels (n = 54); the procedure was bilateral in 16 rabbits and unilateral in 22. Fifteen lovastatin-treated and 15 control rabbits survived 39 days after angioplasty and were then killed. Angiograms, obtained before and 10 min and 39 days after balloon angioplasty, were read with use of electronic calipers by two observers who had no knowledge of treatment data. After the rabbits were killed, vessels were pressure perfused using a standardized protocol to maintain in vivo dimensions for blinded quantitative histologic analysis.(ABSTRACT TRUNCATED AT 250 WORDS)

This article has been cited by other articles:

				D. Pierre-Paul and V. Gahtan Noncholesterol-Lowering Effects of Statins Vascular and Endovascular Surgery, September 1, 2003; 37(5): 301 - 313. [Abstract] [PDF]

				P. V. Oemrawsingh, G. S. Mintz, M. J. Schalij, A. H. Zwinderman, J. W. Jukema, and E. E.v.d. Wall Intravascular Ultrasound Guidance Improves Angiographic and Clinical Outcome of Stent Implantation for Long Coronary Artery Stenoses: Final Results of a Randomized Comparison With Angiographic Guidance (TULIP Study) Circulation, January 7, 2003; 107(1): 62 - 67. [Abstract] [Full Text] [PDF]

				G. Sopko Preventing Cardiac Events and Restenosis After Percutaneous Coronary Intervention JAMA, June 26, 2002; 287(24): 3259 - 3261. [Full Text] [PDF]

				C. Indolfi, A. Cioppa, E. Stabile, E. Di Lorenzo, G. Esposito, A. Pisani, A. Leccia, L. Cavuto, A. M. Stingone, A. Chieffo, et al. Effects of hydroxymethylglutaryl coenzyme A reductase inhibitor simvastatin on smooth muscle cell proliferation in vitro and neointimal formation in vivo after vascular injury J. Am. Coll. Cardiol., January 1, 2000; 35(1): 214 - 221. [Abstract] [Full Text] [PDF]

				P.J. de Feyter Editorials: Lipids and coronary restenosis: an elusive link Eur. Heart J., October 1, 1999; 20(19): 1371 - 1374. [PDF]

				A. Kleemann, S. Eckert, A. von Eckardstein, W. Lepper, U. Schernikau, U. Gleichmann, P. Hanrath, E. Fleck, A. Neiss, S. Kerber, et al. Effects of lovastatin on progression of non-dilated and dilated coronary segments and on restenosis in patients after PTCA. The Cholesterol Lowering Atherosclerosis PTCA Trial (CLAPT) Eur. Heart J., October 1, 1999; 20(19): 1393 - 1406. [Abstract] [PDF]

				C. Guijarro, L. M. Blanco-Colio, M. Ortego, C. Alonso, A. Ortiz, J. J. Plaza, C. Diaz, G. Hernandez, and J. Egido 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase and Isoprenylation Inhibitors Induce Apoptosis of Vascular Smooth Muscle Cells in Culture Circ. Res., September 7, 1998; 83(5): 490 - 500. [Abstract] [Full Text] [PDF]

				A. Gershlick Endovascular manipulation to restrict restenosis Vascular Medicine, August 1, 1998; 3(3): 177 - 188. [Abstract] [PDF]

				A. Lafont and D. Faxon Why do animal models of post-angioplasty restenosis sometimes poorly predict the outcome of clinical trials? Cardiovasc Res, July 1, 1998; 39(1): 50 - 59. [Full Text] [PDF]

				H. Kato, R. Okada, K. Oogushi, S. Emura, H. Kishikawa, S. Kawazoye, M. Fukuoka, T. Takashima, and K. Ohmori Suppressive Effect of Simvastatin on Intramural Small Coronary Arterial Lesions in Cholesterol-Fed Rabbits Angiology, March 1, 1998; 49(3): 211 - 220. [Abstract] [PDF]

				S. Colli, S. Eligini, M. Lalli, M. Camera, R. Paoletti, and E. Tremoli Vastatins Inhibit Tissue Factor in Cultured Human Macrophages: A Novel Mechanism of Protection Against Atherothrombosis Arterioscler Thromb Vasc Biol, February 1, 1997; 17(2): 265 - 272. [Abstract] [Full Text]

				C. Bauters, J.-M. Lablanche, E. P. McFadden, M. Hamon, and M. E. Bertrand Relation of Coronary Angioscopic Findings at Coronary Angioplasty to Angiographic Restenosis Circulation, November 1, 1995; 92(9): 2473 - 2479. [Abstract] [Full Text]

				W. S. Weintraub, S. J. Boccuzzi, J. L. Klein, A. S. Kosinski, S. B. King, R. Ivanhoe, J. C. Cedarholm, M. E. Stillabower, J. D. Talley, S. J. DeMaio, et al. Lack of Effect of Lovastatin on Restenosis after Coronary Angioplasty N. Engl. J. Med., November 17, 1994; 331(20): 1331 - 1337. [Abstract] [Full Text]